Legal & General Group
ARLZ

Legal & General Group’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Legal & General Group’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-5,723
Closed -$20K – 2998
2016
Q1 		$20K Buy
+5,723
New +$29.5K ﹤0.01% 2673

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
TLCM
Tiger Legatus Capital Management New York $62.4M AUM 24.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Legal & General Group's ARLZ Position: Q2 2016 in Review

Legal & General Group sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q2 2016, closing a stake of 5,723 shares — an estimated $20K sold.

Legal & General Group first reported a position in ARLZ in Q1 2016 and held it in 1 quarter. The position peaked at $20K in Q1 2016. 95 funds tracked by Wall St. Rank hold ARLZ as of Q2 2016.

  • Legal & General Group reported no remaining Aralez Pharmaceuticals Inc. position as of Q2 2016 after selling out during the quarter.
  • Legal & General Group sold 5,723 Aralez Pharmaceuticals Inc. shares in Q2 2016, an estimated $20K.
  • Legal & General Group first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 1 quarter.
  • Legal & General Group's Aralez Pharmaceuticals Inc. position peaked at $20K in Q1 2016.
  • 95 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q2 2016.

Based on Legal & General Group's 13F filing for Q2 2016, filed 16 Aug 2016.